Weekly Analysts’ Ratings Changes for Kyverna Therapeutics (KYTX)

Several brokerages have updated their recommendations and price targets on shares of Kyverna Therapeutics (NASDAQ: KYTX) in the last few weeks:

• 11/11/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/5/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/29/2025 – Kyverna Therapeutics had its price target raised by analysts at Wells Fargo & Company from $27.00 to $31.00. They now have an “overweight” rating on the stock.
• 10/27/2025 – Kyverna Therapeutics had its price target raised by analysts at HC Wainwright from $10.00 to $20.00. They now have a “buy” rating on the stock.
• 10/14/2025 – Kyverna Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – Kyverna Therapeutics had its price target raised by analysts at Wells Fargo & Company from $24.00 to $27.00. They now have an “overweight” rating on the stock.
• 9/27/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.